BIO-TECHNE Stock Price, News & Analysis (NASDAQ:TECH)

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE declared a quarterly dividend on Tuesday, August 6th. Shareholders of record on Friday, August 16th will be given a dividend of $0.32 per share on Friday, August 30th. This represents a $1.28 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, August 15th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) posted its earnings results on Tuesday, August, 6th. The biotechnology company reported $1.25 EPS for the quarter, topping the consensus estimate of $1.17 by $0.08. The biotechnology company had revenue of $191.66 million for the quarter, compared to the consensus estimate of $196.37 million. BIO-TECHNE had a return on equity of 13.20% and a net margin of 13.45%. The firm's revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the business posted $1.34 earnings per share. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for BIO-TECHNE.

5 Wall Street analysts have issued twelve-month price targets for BIO-TECHNE's shares. Their predictions range from $165.00 to $270.00. On average, they expect BIO-TECHNE's share price to reach $204.80 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Media coverage about TECH stock has trended negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIO-TECHNE earned a news impact score of -2.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 836,100 shares, an increase of 8.4% from the July 31st total of 771,200 shares. Based on an average daily volume of 152,200 shares, the days-to-cover ratio is currently 5.5 days. Currently, 2.2% of the company's stock are short sold. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), Adaptive Biotechnologies (ADPT), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Allogene Therapeutics (ALLO), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Celgene (CELG), Gilead Sciences (GILD), Amgen (AMGN), Illumina (ILMN), AbbVie (ABBV), General Electric (GE), Akorn (AKRX) and GW Pharmaceuticals PLC- (GWPH).

BIO-TECHNE's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.06%), BlackRock Inc. (10.06%), Vanguard Group Inc. (9.27%), Brown Capital Management LLC (4.33%), Bamco Inc. NY (4.14%) and Janus Henderson Group PLC (3.65%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, First Trust Advisors LP, Schroder Investment Management Group, Kornitzer Capital Management Inc. KS, Citadel Advisors LLC, Brown Capital Management LLC, Bank of America Corp DE and Riverbridge Partners LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, BNP Paribas Arbitrage SA, Vanguard Group Inc., Cubist Systematic Strategies LLC, Voloridge Investment Management LLC, DekaBank Deutsche Girozentrale and Pacer Advisors Inc.. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $200.43.

BIO-TECHNE has a market capitalization of $7.59 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]